Episodic Migraine Clinical Trial
Official title:
fMRI of the Brainstem in Migraine Sufferers and Controls. Does Iron Deposition Correlate With Progression of Disease?
This is a 2 visit research study for patients with or without a diagnosis of migraine.
Participants will be administered informed consent, have a medical history taken and a
physical examination performed, and complete 3 questionnaires at the first visit. The
participants will have a functional MRI performed after completion of Visit 1. Study
stipends will be given for each completed research visit.
The purpose of this study is to potentially identify risk factors and/or biomarkers (which
are differences in the brain structures)by comparing the brain MRI scans of migraine
sufferers to brain scans of control persons to attempt to identify migraine progression
using the functional MRI scans.
At Visit 1, patients in 3 diagnostic arms,(consisting of subjects with episodic migraine,
chronic daily migraine or non-migraineurs/controls), of 11 subjects each, will be consented
and then have a physical exam, medical history and current medication use documented. Each
of these enrolled subjects will have a PRIME MD assessment administered, and will complete
the MIDAS and ASC-12 questionnaires.
At Visit 2 these same subjects will have an fMRI performed.
Subjects will be greater than age 18, have the appropriate diagnoses, be able to be
consented and not be pregnant or have an inability to have the fMRI performed (have
implanted metal devices, have severe claustrophobia).
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06047457 -
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
|
Phase 3 | |
Completed |
NCT02569853 -
DFN-11 Injection in Episodic Migraine With or Without Aura
|
Phase 3 | |
Completed |
NCT00719134 -
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
|
Phase 4 | |
Completed |
NCT03700320 -
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
Recruiting |
NCT05042037 -
Probiotics as Adjunctive Migraine Prophylaxis
|
N/A | |
Recruiting |
NCT04628429 -
CGRP Inhibition, Autonomic Function, and Migraine
|
||
Active, not recruiting |
NCT05028569 -
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
|
Phase 3 | |
Withdrawn |
NCT01257893 -
Aspirin Resistance in Women With Migraine
|
N/A | |
Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
Completed |
NCT03132233 -
Energy for the Brain
|
N/A | |
Completed |
NCT03939312 -
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
|
Phase 3 | |
Completed |
NCT03927144 -
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
|
Phase 4 | |
Recruiting |
NCT06248671 -
Prophylactic Treatment With Atorvastatin for Episodic Migraine.
|
Phase 2 | |
Recruiting |
NCT05711394 -
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
|
Phase 3 | |
Recruiting |
NCT05449145 -
The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine
|
N/A | |
Completed |
NCT04031781 -
The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis
|
N/A | |
Completed |
NCT05264129 -
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
|
Phase 4 | |
Completed |
NCT04740827 -
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
|
Phase 3 |